KRT88P and infection: HBV reactivation is defined in the 2018 AASLD guidelines as “the loss of HBV immune control in HBsAg-positive, anti-HBc-positive or HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy for a concomitant medical condition” [10] and reflects the host immune system’s inability to control the infection.